Beijing Anlong Biopharmaceutical

Beijing Anlong Biopharmaceutical is a clinical-stage biotechnology company founded in 2020, specializing in the development of genetic medicines. The company leverages its proprietary Adeno-Associated Virus (AAV) vector and small interfering RNA (siRNA) technology platforms to create treatments for a variety of conditions. Anlong Bio's primary business model focuses on in-house research and development, clinical trials, and strategic partnerships with other pharmaceutical companies for product and market collaborations.

The company's pipeline includes gene therapies for ophthalmic diseases such as wet age-related macular degeneration (wAMD) and diabetic retinopathy (DR). Its leading candidate for these conditions, which expresses Aflibercept, has entered Phase II clinical trials and is noted as the first of its kind to be administered via the suprachoroidal space. Beyond ophthalmology, Anlong Bio is developing siRNA drugs targeting metabolic disorders, weight loss, neurological conditions, and muscular diseases, while also exploring applications in respiratory, gynecology, immune, and oncology fields. The company aims to provide affordable and innovative genetic medicines to a global market.

Since its founding, Anlong Bio has progressed through several funding rounds, including a Seed round in July 2020, a Series A in June 2021, and a Series A1 in December 2023. The company is backed by multiple investors, including CITIC Medical & Health Group, Highlight Capital, and Beijing Shunyi Technology Innovation, among others.

Keywords: gene therapy, siRNA technology, AAV vectors, drug development, biotechnology, wet macular degeneration, diabetic retinopathy, metabolic disorders, clinical trials, genetic medicine, biopharmaceutical, ophthalmology, suprachoroidal administration, Aflibercept, drug discovery, life sciences, venture capital-backed, genetic drug development, neurology, oncology